Home / Pharmaceutical / Accountable Care Organizations - A Building Block for the Future of Health Care

Accountable Care Organizations - A Building Block for the Future of Health Care

Published: Mar 2015 | No Of Pages: 53 | Published By: CBR Pharma Insights

The Accountable Care Act promoted ACOs through a variety of programs: Comprehensive Primary Care Initiative, Partnerships for Patients Initiative, Pioneer and Advanced Payment ACO Models and Medicare Shared Savings Program for ACOs. The central program is the Medicare Shared Savings Program, under which ACOs gradually share in the cost savings they achieve through providing coordinated and consistent care to groups of Medicare beneficiaries while meeting quality targets.

The focus of ACOs is coordinated care, ease-of-access, care management models, evidence-based care, technology use for data management, and clinical integration. This may mean some changes for pharmaceutical companies looking to work with ACOs. Promotional materials will need to highlight evidence-based medicine findings and detailing should highlight potential cost efficiencies. Patient outreach aspects of ACOs will give pharmaceutical companies an opportunity to provide patient educational materials.

The report, Accountable Care Organizations - A Building Block for the Future of Health Care has been written to support corporate strategy, managed markets, business insights, and product strategy teams through its analysis of the changes taking place in the health care landscape and the impact ACOs will have on the way patients are treated. As an integral part of Health Care Reform in the US, pharmaceutical companies must understand how ACOs will work, and in turn, affect their current and future business.

Scope

  • Development of ACOs
  • Health care community response
  • Case studies
  • What ACOs mean for pharmaceutical companies
  • Future Outlook

Key Reasons to Purchase

  • Understand the final rules for the governments ACO programs
  • Analyze the ways ACOs may impact pharmaceutical promotional activities
  • Gain insights through the examination of cases study analysis of the potential for ACOs to bring reform forward
  • Understand the challenges ACOs face now and in the future
  • Assess the opportunities ACOs can bring to pharmaceutical companies

Executive Summary
Chapter 1: Development of ACOs
Background
Health care reform of 2010
ACO Programs
Comprehensive Primary Care Initiative
Partnerships for Patients Initiative
Pioneer and Advance Payment ACO Models
Medicare Shared Savings Program
Final rules

Chapter 2: Health care community response
Physician response
Patient response

Chapter 3: Case Studies
Case study one: better rates for breast cancer screening through coordinated teams
Case study two: easier neurological care with a simple change
Case study three: finding more cost-effective ways to treat mental health
Case study four: decreasing infections through evidence-based care
Case study five: using technology to help care for heart disease patients
Case study six: improving Diabetes outcomes with a care management model

Chapter 4: What ACOs mean for pharmaceutical companies
Evidence-based medicine and promotion
Changes for detailing
Educational materials for patients
Educational programs for physicians
Opportunities for growth

Chapter 5: What ACOs wont do
Large scale change might not be achievable
Hospitals rather than doctors may be empowered
Patients may reject the model
The test run of the ACO model was not a clear success

Chapter 6: The outlook for ACOs
The Supreme Court decision
The November elections
Electronic health records
Data management
Appendix

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +